Evidence map›Paper›PMID 42473178›Full record

ArticleGenetics research2026

CDC20 Regulates the Progression of Clear Cell Renal Cell Carcinoma via the Wnt/β-Catenin Signaling Pathway.

YuHu Hao, Leizuo Zhao, Yanning Sun, Fan Peng, Tingting Xu, Wentao Deng, Qinghua Xia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genetics research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

YuHu HaoDepartment of Urology, Shandong Provincial Hospital, Shandong University, Jinan 250021, China, sdu.edu.cn.ORCID https://orcid.org/0009-0004-0880-5425
Leizuo ZhaoDepartment of Urology, Dongying People's Hospital, Dongying 257000, China, dysrmyy.com/.
Yanning SunDepartment of Urology, Shandong Provincial Hospital, Shandong University, Jinan 250021, China, sdu.edu.cn.
Fan PengDepartment of Urology, Shandong Provincial Hospital, Shandong University, Jinan 250021, China, sdu.edu.cn.
Tingting XuDepartment of Urology, Dongying People's Hospital, Dongying 257000, China, dysrmyy.com/.
Wentao DengDepartment of Urology, Dongying People's Hospital, Dongying 257000, China, dysrmyy.com/.
Qinghua XiaDepartment of Urology, Shandong Provincial Hospital, Shandong University, Jinan 250021, China, sdu.edu.cn.ORCID https://orcid.org/0009-0002-0352-067X

Funding

Medical and Health Science and Technology Development Project of Shandong Province 202104050603National Natural Science Foundation of China 82272813Traditional Chinese Medicine Science & Technology Project of Shandong Province M-2022036
6 · The paper itself

Abstract

objectiveTo detect the expression level of cell division cycle 20 homolog (CDC20) in clear cell renal cell carcinoma (ccRCC) and to study the biological function of CDC20 in ccRCC.

methodsCDC20 expression levels and clinical significance of ccRCC were determined using the Cancer Genome Atlas (TCGA) database. We detected the expression level of CDC20 in ccRCC with the help of immunohistochemistry (IHC). The effect of CDC20 on the proliferation of renal cancer cells was investigated using EDU and CCK-8 proliferation assays. We used wound healing assays and Transwell assays to determine the effects of CDC20 on renal cancer cell migration and invasion and Wnt signaling pathway agonists in recovery experiments. The mechanism of CDC20 in ccRCC was detected using western blotting. Finally, the effect of CDC20 on renal cancer cells was verified in vivo in a nude mouse xenograft model.

resultsBioinformatics analysis found that CDC20 was upregulated in ccRCC, and its high expression was associated with poor prognosis in kidney renal cell carcinoma (KIRC) patients. In addition, we detected high expression of CDC20 in KIRC tissues, consistent with the results of bioinformatics analysis. Besides, knockdown of CDC20 can inhibit the biological functions of renal cancer cells. The recovery experiment proved that the biological function of the originally inhibited renal cancer cells was restored. In vivo, low expression of CDC20 can inhibit tumor growth.

conclusionsAs CDC20 is highly expressed in KIRC tissues, it can be used as both a therapeutic target and a prognostic marker.

Indexed as

Carcinoma, Renal CellCdc20 ProteinsKidney NeoplasmsWnt Signaling PathwayAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, NudeMiddle AgedCDC20 protein, humanCdc20 ProteinsccRCCCDC20metastasisproliferationWnt signaling pathway

Identifiers

PMID42473178
PMCPMC13382150

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.